Global Psychiatry Partnering 2010-2016: Deal trends, players and financials

Publisher Name :
Date: 01-Nov-2016
No. of pages: 700
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Psychiatry Partnering 2010 to 2016 provides the full collection of Psychiatry disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Psychiatry partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Psychiatry partnering agreement structure

Psychiatry partnering contract documents

Top Psychiatry deals by value

Most active Psychiatry dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Psychiatry deals.

The report presents financial deal terms values for Psychiatry deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Psychiatry dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Psychiatry dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Psychiatry deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Psychiatry dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Psychiatry deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Psychiatry partnering deals by specific Psychiatry target announced since 2010. The chapter is organized by specific Psychiatry therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Psychiatry partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Psychiatry partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Psychiatry technologies and products.

Report scope

Global Psychiatry Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Psychiatry trends and structure of deals entered into by leading companies worldwide.

Global Psychiatry Partnering 2010 to 2016 includes:

Trends in Psychiatry dealmaking in the biopharma industry since 2010

Analysis of Psychiatry deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Psychiatry deal contract documents

Comprehensive access to over 3500 Psychiatry deal records

The leading Psychiatry deals by value since 2010

Most active Psychiatry dealmakers since 2010

The report includes deals for the following indications: Akathisia, Anxiety disorder, Generalised anxiety disorder, Panic disorder, Post traumatic stress disorder, Attention deficit hyperactivity disorder, Bipolar disorder, Chronic fatigue syndrome, Cognitive impairment, Delirium, Dementia, Alzheimers, Dementia with lewy bodies, Vascular dementia, Depression, Dystonia, Eating disorder, Anorexia, Bulimia, Learning disability, Aspergers, Autism, Mania, Obsessive compulsive disorder, Personality disorder, Schizophrenia, Sleep disorders, Insomnia, Narcolepsy, Sleep apnoea, Tardive dyskinesia, Tourettes, plus other psychiatric indications.

In Global Psychiatry Partnering 2010 to 2016, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Psychiatry Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 600 psychiatry deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Psychiatry Partnering 2010 to 2016 provides the reader with the following key benefits:

In-depth understanding of Psychiatry deal trends since 2010

Access Psychiatry deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Psychiatry partner companies

Comprehensive access to over 750 links to actual Psychiatry deals entered into by the world's biopharma companies

Indepth review of Psychiatry deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Psychiatry opportunities

Uncover companies actively partnering Psychiatry opportunities

Global Psychiatry Partnering 2010-2016: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Psychiatry dealmaking
2.1. Introduction
2.2. Psychiatry partnering over the years
2.3. Psychiatry partnering by deal type
2.4. Psychiatry partnering by industry sector
2.5. Psychiatry partnering by stage of development
2.6. Psychiatry partnering by technology type
2.7. Psychiatry partnering by therapeutic indication

Chapter 3 -Financial deal terms for Psychiatry partnering
3.1. Introduction
3.2. Disclosed financials terms for Psychiatry partnering
3.3. Psychiatry partnering headline values
3.4. Psychiatry deal upfront payments
3.5. Psychiatry deal milestone payments
3.6. Psychiatry royalty rates

Chapter 4 - Leading Psychiatry deals and dealmakers
4.1. Introduction
4.2. Most active in Psychiatry partnering
4.3. List of most active dealmakers in Psychiatry
4.4. Top Psychiatry deals by value

Chapter 5 - Psychiatry contract document directory
5.1. Introduction
5.2. Psychiatry partnering deals where contract document available

Chapter 6 - Psychiatry dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Psychiatry therapeutic target

Appendices
Appendix 1 - Directory of Psychiatry deals by company A-Z 2010 to 2016
Appendix 2 - Directory of Psychiatry deals by deal type 2010 to 2016
Appendix 3 - Directory of Psychiatry deals by stage of development 2010 to 2016
Appendix 4 - Directory of Psychiatry deals by technology type 2010 to 2016
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Tables and Figures

Figure 1: Psychiatry partnering since 2010
Figure 2: Psychiatry partnering by deal type since 2010
Figure 3: Psychiatry partnering by industry sector since 2010
Figure 4: Psychiatry partnering by stage of development since 2010
Figure 5: Psychiatry partnering by technology type since 2010
Figure 6: Psychiatry partnering by indication since 2010
Figure 7: Psychiatry deals with a headline value
Figure 8: Psychiatry deals with upfront payment values
Figure 9: Psychiatry deals with milestone payment
Figure 10: Psychiatry deals with royalty rates
Figure 11: Active Psychiatry dealmaking activity- 2010 to 2016
Figure 12: Top Psychiatry deals by value since 2010
  • United States Trazodone Hydrochloride Market by Manufacturers, Type and Application, Forecast to 2021
    Published: 06-Dec-2016        Price: US 4480 Onwards        Pages: 109
    Chocolate is a typically sweet, usually brown, food preparation of theobroma cacao seeds, roasted and ground, often flavored, as with vanilla. It is made in the form of a liquid, paste, or in a block, or used as a flavoring ingredient in other foods. Scope of the Report: This report focuses on the Trazodone Hydrochloride in United States market. This report categorizes the market based on manufacturers, type and application. Market Segment by Manufacturers, this rep......
  • China Codeine Market Research Report 2016
    Published: 05-Dec-2016        Price: US 3200 Onwards        Pages: 110
    Notes: Sales, means the sales volume of Codeine Revenue, means the sales value of Codeine This report studies Codeine in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Macfarian Smith - Francopia - Noramco - Weifa - Mallinckrodt - Temad - GSK - Alkaloida - Tas. Alkaloids - Alcaliber - Fine......
  • United States Trazodone Hydrochloride (API) Market Report 2016
    Published: 30-Nov-2016        Price: US 3800 Onwards        Pages: 113
    Notes: Sales, means the sales volume of Trazodone Hydrochloride (API) Revenue, means the sales value of Trazodone Hydrochloride (API) This report studies sales (consumption) of Trazodone Hydrochloride (API) in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Teva - Angelini - Mylan - Fermion - The Piramal Group Split by product Types, with sales,......
  • Global ADHD Drugs Sales Market Report 2016
    Published: 30-Nov-2016        Price: US 4000 Onwards        Pages: 104
    Notes: Sales, means the sales volume of ADHD Drugs Revenue, means the sales value of ADHD Drugs This report studies sales (consumption) of ADHD Drugs in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Eli Lilly - Janssen Pharmaceuticals, Inc. - Shire - Perdue Pharma - Glaxosmit......
  • United States Antidepressant Market Report 2016
    Published: 30-Nov-2016        Price: US 3800 Onwards        Pages: 104
    Notes: Sales, means the sales volume of Antidepressant Revenue, means the sales value of Antidepressant This report studies sales (consumption) of Antidepressant in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Pfizer, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Claire Ellen Products, Inc. (US) - Eli Lilly and Company (US) - GlaxoSmithKline Plc ......
  • Global Imipramine Hydrochloride (API) Market Research Report 2016
    Published: 29-Nov-2016        Price: US 2900 Onwards        Pages: 104
    Notes: Production, means the output of Imipramine Hydrochloride (API) Revenue, means the sales value of Imipramine Hydrochloride (API) This report studies Imipramine Hydrochloride (API) in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering - Teva Pharmaceutical Industries - Mal......
  • Europe Codeine Market Report 2016
    Published: 28-Nov-2016        Price: US 3900 Onwards        Pages: 116
    Notes: Sales, means the sales volume of Codeine Revenue, means the sales value of Codeine This report studies sales (consumption) of Codeine in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Macfarian Smith - Francopia - Noramco - Weifa - Mallinckrodt - Tema......
  • United States Risperidone Market Report 2016
    Published: 25-Nov-2016        Price: US 3800 Onwards        Pages: 106
    Notes: Sales, means the sales volume of Risperidone Revenue, means the sales value of Risperidone This report studies sales (consumption) of Risperidone in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Janssen Pharmaceutica - Teva - Sun Pharmaceutical - Aurobindo - Cipla - Invent Farma Group - Medichem - Interquim - IPCA - ......
  • Global Imipramine Hydrochloride (API) Market Professional Survey Report 2016
    Published: 25-Nov-2016        Price: US 3500 Onwards        Pages: 101
    Notes: Production, means the output of Imipramine Hydrochloride (API) Revenue, means the sales value of Imipramine Hydrochloride (API) This report studies Imipramine Hydrochloride (API) in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs